"ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific" was originally created and published by ...

Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

Bristol Myers Squibb is ending its collaboration with Immatics on IMA401, effective December 12, as part of portfolio ...

Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, maintained its Outperform rating and $16.00 price target from Mizuho. The affirmation follows recent developments including the ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Immatics (IMTX – Research Report) on September 8. The company’s ...

An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a foreign company.

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Mizuho has reiterated its Outperform rating on Immatics (NASDAQ:IMTX), maintaining the stock's price target at $16.00. The endorsement comes after Immatics announced initial Phase 1 data for ...